Shots:

• The US FDA unveiled 5yr. action plan to foster drug development & simplifying patient access to novel treatments as well as improve and extends the lives of people suffering from neurodegenerative disease inc. ALS
• This new strategy is part of the accelerating access to critical therapies for ALS Act or ACT for ALS. It includes provisions for the Department of HHS to award grants & contracts to public & private entities for R&D
• The US FDA focuses to understand disease pathogenesis & natural history, support patient access to new drugs and bolster relevant clinical trial infrastructure. Please keep an eye on this space for further details on this topic

Ref: PRNewswire | Image: US FDA